215 related articles for article (PubMed ID: 38278146)
1. Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactions.
Zhu Y; Tang S; Yuan Q; Fu J; He J; Liu Z; Zhao X; Li Y; Zhao Y; Zhang Y; Zhang X; Zhang Y; Zhu Y; Wang W; Zheng B; Wu R; Wu T; Yang S; Qiu X; Shen S; Hu J; Chen L; Wang Y; Wang H; Gao D; Chen L
Cell Rep Med; 2024 Feb; 5(2):101375. PubMed ID: 38278146
[TBL] [Abstract][Full Text] [Related]
2. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity.
Shi X; Li Y; Yuan Q; Tang S; Guo S; Zhang Y; He J; Zhang X; Han M; Liu Z; Zhu Y; Gao S; Wang H; Xu X; Zheng K; Jing W; Chen L; Wang Y; Jin G; Gao D
Nat Commun; 2022 Apr; 13(1):2169. PubMed ID: 35449156
[TBL] [Abstract][Full Text] [Related]
3. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
4. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers.
Li L; Selaru FM
Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704
[TBL] [Abstract][Full Text] [Related]
6. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
7. Organoids as research models for hepatocellular carcinoma.
Yu JH; Ma S
Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
[TBL] [Abstract][Full Text] [Related]
8. Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
Mo S; Tang P; Luo W; Zhang L; Li Y; Hu X; Ma X; Chen Y; Bao Y; He X; Fu G; Xu X; Rao X; Li X; Guan R; Chen S; Deng Y; Lv T; Mu P; Zheng Q; Wang S; Liu F; Li Y; Sheng W; Huang D; Hu C; Gao J; Zhang Z; Cai S; Clevers H; Peng J; Hua G
Adv Sci (Weinh); 2022 Nov; 9(31):e2204097. PubMed ID: 36058001
[TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
[TBL] [Abstract][Full Text] [Related]
10. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
11. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q
Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
Ren X; Chen W; Yang Q; Li X; Xu L
J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Yan HHN; Siu HC; Law S; Ho SL; Yue SSK; Tsui WY; Chan D; Chan AS; Ma S; Lam KO; Bartfeld S; Man AHY; Lee BCH; Chan ASY; Wong JWH; Cheng PSW; Chan AKW; Zhang J; Shi J; Fan X; Kwong DLW; Mak TW; Yuen ST; Clevers H; Leung SY
Cell Stem Cell; 2018 Dec; 23(6):882-897.e11. PubMed ID: 30344100
[TBL] [Abstract][Full Text] [Related]
15. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacogenomic Landscape in Human Liver Cancers.
Qiu Z; Li H; Zhang Z; Zhu Z; He S; Wang X; Wang P; Qin J; Zhuang L; Wang W; Xie F; Gu Y; Zou K; Li C; Li C; Wang C; Cen J; Chen X; Shu Y; Zhang Z; Sun L; Min L; Fu Y; Huang X; Lv H; Zhou H; Ji Y; Zhang Z; Meng Z; Shi X; Zhang H; Li Y; Hui L
Cancer Cell; 2019 Aug; 36(2):179-193.e11. PubMed ID: 31378681
[TBL] [Abstract][Full Text] [Related]
17. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
Wang W; Yuan T; Ma L; Zhu Y; Bao J; Zhao X; Zhao Y; Zong Y; Zhang Y; Yang S; Qiu X; Shen S; Wu R; Wu T; Wang H; Gao D; Wang P; Chen L
Adv Sci (Weinh); 2022 Aug; 9(22):e2105810. PubMed ID: 35665491
[TBL] [Abstract][Full Text] [Related]
19. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
20. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
